NCT06771674 Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma Status COMPLETED Phase N/A
NCT06771622 Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT06771544 Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma Status RECRUITING Phase PHASE2
NCT06770582 Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial Status RECRUITING Phase PHASE2
NCT06764875 A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer Status RECRUITING Phase PHASE3
NCT06764095 Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Status RECRUITING Phase PHASE4
NCT06758401 This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. Status RECRUITING Phase PHASE3
NCT06745882 Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC Status RECRUITING Phase PHASE2
NCT06743126 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma Status RECRUITING Phase PHASE3
NCT06731907 A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) Status RECRUITING Phase PHASE2
NCT06731478 Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer Status RECRUITING Phase PHASE3
NCT06731270 Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy Status RECRUITING Phase PHASE2
NCT06724042 Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors Status NOT_YET_RECRUITING Phase PHASE1
NCT06724016 Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors Status RECRUITING Phase PHASE1
NCT06719362 A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies Status RECRUITING Phase PHASE1
NCT06716853 A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma Status TERMINATED Phase PHASE1/PHASE2
NCT06712316 Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer Status RECRUITING Phase PHASE2/PHASE3
NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Status RECRUITING Phase PHASE3
NCT06708858 Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer Status RECRUITING Phase PHASE2
NCT06699212 A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases Status RECRUITING Phase PHASE3